Cat. No.: HY-114392

Gly-β-MCA

28 Cited Publications

Avis client

Based on 28 publication(s) in Google Scholar

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.75%
CAS No.: 66225-78-3
Formule: C₂₆H₄₃NO₆
Masse moléculaire:465.62

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Gly-β-MCA Chemical Structure

CAS No.: 66225-78-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (28)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders^[1].

IC₅₀ & Target

FXR^[1].

In Vitro

Gly-β-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor^[1].
Gly-β-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice^[1].
Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 66225-78-3
Appearance Solid
Masse moléculaire 465.62
Formule C₂₆H₄₃NO₆
Color White to off-white
SMILES

C[C@@H]([C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([C@]4(CC[C@@H](O)C[C@H]4[C@H](O)[C@@H]3O)C)([H])CC[C@]12C)CCC(NCC(O)=O)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (28)

All RT-PCRFlow CytometryCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Cancer Cell

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. [Abstract]

2024 Aug 12;42(8):1386-1400.e8. PMID: 39137727

Gly-β-MCA purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Aug 12;42(8):1386-1400.e8. [Abstract]

Cell viability at OD570 of allocholic acid-treated CRC cells after using FXR1 antagonist glycine-β-muricholic acid (50 μM).

Gly-β-MCA purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Aug 12;42(8):1386-1400.e8. [Abstract]

Gly-β-MCA (50 μM). Protein expression of cell proliferation, cell cycle, or MAPK pathway markers in CRC cells.
Cell Metab

Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. [Abstract]

2023 Oct 3;35(10):1752-1766.e8. PMID: 37591244

Gly-β-MCA purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Oct 3;35(10):1752-1766.e8. [Abstract]

Gly-β-MCA (10 mg/kg). Protein expression of CYP7A1 and CYP7B1 in the liver.
Microbiome

Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets. [Abstract]

2024 Feb 5;12(1):20. PMID: 38317217

Gly-β-MCA purchased from MedChemExpress. Usage Cited in: Microbiome. 2024 Feb 5;12(1):20. [Abstract]

The expression of SLA-I was analyzed by flow cytometry in the presence and absence of SBI-115 and Gly-β-MCA (2 μM) in IPEC-J2 cells treated with 20 μM LCA for 12 h.
Adv Sci (Weinh)

Gut Microbiota-Derived Hyocholic Acid Enhances Type 3 Immunity and Protects Against Salmonella enterica Serovar Typhimurium in Neonatal Rats. [Abstract]

2024 Dec 31:e2412071. PMID: 39737849

Gly-β-MCA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 31:e2412071. [Abstract]

RT‐qPCR analysis of Wtap and Rorc mRNA levels in rat intestinal γδT cells and ILC3s with with HCA, Gly-β-MCA (10 μM; 16 h), GW4064 treatment.
Pharmacol Res

Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis. [Abstract]

2023 Oct:196:106902. PMID: 37657657
Phytomedicine

Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii. [Abstract]

2023 Dec:121:155054. PMID: 37738906
J Transl Med

Chronic proton pump inhibitor exposure aggravates intestinal injury by impairing intestinal stem cell self-renewal through the microbiota-7-ketolithocholic acid Axis. [Abstract]

2026 Jun 18. PMID: 42316284
J Transl Med

Quantitative proteomic and phosphoproteomic analysis reveal the relationship between mitochondrial dysfunction and cytoskeletal remodeling in hiPSC-CMs deficient in PINK1. [Abstract]

2023 Aug 30;21(1):581. PMID: 37649075
Food Res Int

Fermented grape pomace alleviates Salmonella typhimurium-induced Hepatointestinal inflammation: FXR mediates protection by orchestrating bile acid homeostasis and suppressing the colonic NLRP3 Inflammasome. [Abstract]

2026 May 1;231(Pt 2):118797. PMID: 41819900
J Pineal Res

Melatonin mitigates aflatoxin B1-induced liver injury via modulation of gut microbiota/intestinal FXR/liver TLR4 signaling axis in mice. [Abstract]

2022 Sep;73(2):e12812. PMID: 35652241
J Ethnopharmacol

Dabupi decoction mitigates fluorouracil-induced intestinal mucositis via farnesoid X receptor activation and dihydropyrimidine dehydrogenase upregulation. [Abstract]

2026 Aug 10:367:121742. PMID: 42069161
J Ethnopharmacol

Gut microbiota-based bile acid metabolism mediates the intestinal barrier protection of Phellodendri chinensis Cortex polysaccharide against ulcerative colitis. [Abstract]

2026 Apr 6:360:121143. PMID: 41490552
J Agric Food Chem

Transcriptomic Analysis Reveals Lactobacillus reuteri Alleviating Alcohol-Induced Liver Injury in Mice by Enhancing the Farnesoid X Receptor Signaling Pathway. [Abstract]

2022 Oct 5;70(39):12550-12564. PMID: 36154116
Food Funct

Pterostilbene attenuates intestinal barrier damage and secondary liver oxidative stress in a murine model of Clostridium difficile infection by regulating the gut microbiota. [Abstract]

2025 May 6;16(9):3325-3343. PMID: 40190207
Life Metab

Development of cyclopeptide inhibitors specifically disrupting FXR-coactivator interaction in the intestine as a novel therapeutic strategy for MASH. [Abstract]

2025 Feb 8;4(2):loaf004. PMID: 40225300
Cells

Glycine-β-Muricholic Acid Improves Liver Fibrosis and Gut Barrier Function by Reducing Bile Acid Pool Size and Hydrophobicity in Male Cyp2c70 Knockout Mice. [Abstract]

2023 May 12;12(10):1371. PMID: 37408204
Commun Biol

The secretory protein, CLCF1, improves cholestatic liver disease by inhibiting hepatic bile acid synthesis and promoting bile acid excretion. [Abstract]

2026 Mar 16;9(1):370. PMID: 41840139
J Lipid Res

Gly-β-MCA is a potent anti-cholestasis agent against "human-like" hydrophobic bile acid-induced biliary injury in mice. [Abstract]

2024 Sep 19:100649. PMID: 39306039
Mol Nutr Food Res

Postbiotics Prepared Using Lactobacillus reuteri Ameliorates Ethanol-Induced Liver Injury by Regulating the FXR/SHP/SREBP-1c Axis. [Abstract]

2024 Jun 27:e2300927. PMID: 38937862
Aquaculture

2021, 736248.
Adv Cancer Biol Metastasis

2026 Feb 13.
Microbiol Spectr

FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strains. [Abstract]

2022 Oct 26;10(5):e0051822. PMID: 36036629
AMB Express

Odoribacter laneus protects intestinal barrier by bile acid-FXR axis in acute pancreatitis. [Abstract]

2026 May 20. PMID: 42162499
Drug Metab Dispos

Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier. [Abstract]

2025 May;53(5):100072. PMID: 40300306
Am J Physiol Gastrointest Liver Physiol

Gly-βMCA modulates bile acid metabolism to reduce hepatobiliary injury in Mdr2 KO mice. [Abstract]

2025 Jul 1;329(1):G45-G57. PMID: 40418643
Curr Med Sci

Targeting the Gut Microbiota-Bile Acid-FXR Axis: The Therapeutic Mechanism of Yudantong Decoction in Cholestatic Liver Disease. [Abstract]

2026 Jun;46(3):851-865. PMID: 42053886
Cell Press Blue

2026 Apr 22.
Research Square Preprint

2021 Sep.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (214.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1477 mL

10.7384 mL

21.4767 mL

5 mM

0.4295 mL

2.1477 mL

4.2953 mL

10 mM

0.2148 mL

1.0738 mL

2.1477 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1477 mL	10.7384 mL	21.4767 mL	53.6919 mL
	5 mM	0.4295 mL	2.1477 mL	4.2953 mL	10.7384 mL
	10 mM	0.2148 mL	1.0738 mL	2.1477 mL	5.3692 mL
	15 mM	0.1432 mL	0.7159 mL	1.4318 mL	3.5795 mL
	20 mM	0.1074 mL	0.5369 mL	1.0738 mL	2.6846 mL
	25 mM	0.0859 mL	0.4295 mL	0.8591 mL	2.1477 mL
	30 mM	0.0716 mL	0.3579 mL	0.7159 mL	1.7897 mL
	40 mM	0.0537 mL	0.2685 mL	0.5369 mL	1.3423 mL
	50 mM	0.0430 mL	0.2148 mL	0.4295 mL	1.0738 mL
	60 mM	0.0358 mL	0.1790 mL	0.3579 mL	0.8949 mL
	80 mM	0.0268 mL	0.1342 mL	0.2685 mL	0.6711 mL
	100 mM	0.0215 mL	0.1074 mL	0.2148 mL	0.5369 mL

Keywords

Gly-β-MCA

28 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Gly-β-MCA

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Autophagy Compound Library

Lipid Compound Library

Anti-Obesity Compound Library

Targeted Diversity Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Bile Acids Library

Publications Citing Use of MedChemExpress (MCE) Gly-β-MCA

Activité biologique

Chemical Information

Publications (28)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Gly-β-MCA

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Autophagy Compound Library

Lipid Compound Library

Anti-Obesity Compound Library

Targeted Diversity Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Bile Acids Library

Publications Citing Use of MedChemExpress (MCE) Gly-β-MCA

Activité biologique

Chemical Information

Publications (28)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Gly-β-MCA Related Classifications

HY-114392 Related Classifications